Scott B Capps
CIK 1409753 · View on SEC EDGAR ↗
Insider
First SEC filing: March 15, 2021 · Latest: March 15, 2021
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 92 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
92 other filings hidden
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Dec. 15, 2020 | AORT | S | 8,366 | $21.34 | $178,530 | 148,640 Direct | -5.33% | Disposed | 39.9% (price as of 2026-08-19) |
| Nov. 26, 2019 | AORT | S | 7,184 | $24.93 | $179,097 | 143,895 Direct | -4.76% | Disposed | 19.7% (price as of 2026-08-19) |
| May 31, 2019 | AORT | S | 2,000 | $28.55 | $57,100 | 141,079 Direct | -1.40% | Disposed | 4.6% (price as of 2026-08-19) |
| Aug. 30, 2018 | AORT | S | 6,332 | $34.10 | $215,921 | 141,087 Direct | -4.30% | Disposed | -12.5% (price as of 2026-08-19) |
| Feb. 22, 2017 | AORT | S | 11,083 | $16.40 | $181,761 | 117,394 Direct | -8.63% | Disposed | 82.0% (price as of 2026-08-19) |
| Feb. 19, 2016 | AORT | S | 418 | $10.30 | $4,305 | 91,873 Direct | -0.45% | Disposed | 189.8% (price as of 2026-08-19) |
| Feb. 19, 2016 | AORT | S | 14,582 | $10.30 | $150,195 | 91,873 Direct | -13.70% | Disposed | 189.8% (price as of 2026-08-19) |
| Nov. 27, 2013 | AORT | S | 25,000 | $10.60 | $265,000 | 68,303 Direct | -26.79% | Disposed | 181.6% (price as of 2026-08-19) |
Showing latest 100 of 101 transactions
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 17, 2021 | AORT | Stock Options (Right to Buy) | Common Stock (10,016) | $24.90 | Feb. 17, 2028 | 10,016 | Acquired |
| Dec. 15, 2020 | AORT | Stock Option (Right to Buy) | Common Stock (10,000) | $9.97 | Feb. 26, 2021 | 10,000 | Disposed |
| May 5, 2020 | AORT | Phantom Stock | Phantom Stock (1,797) | — | — | 1,797 | Acquired |
| Feb. 19, 2020 | AORT | Stock Option(Right to Buy) | Common Stock (9,645) | $26.24 | Feb. 19, 2027 | 9,645 | Acquired |
| Nov. 26, 2019 | AORT | Stock Option (Right to Buy) | Common Stock (10,000) | $6.12 | Feb. 15, 2020 | 10,000 | Disposed |
| March 5, 2019 | AORT | Stock Option (Right to Buy) | Common Stock (7,265) | $29.62 | March 5, 2026 | 7,265 | Acquired |
| Aug. 30, 2018 | AORT | Stock Option (Right to Buy) | Common Stock (8,332) | $5.67 | Feb. 18, 2019 | 8,332 | Disposed |
| March 12, 2018 | AORT | Stock Option (Right to Buy) | Common Stock (9,944) | $21.55 | March 12, 2025 | 9,944 | Acquired |
| Feb. 13, 2018 | AORT | Stock Options (Right to Buy) | Common Stock (31,333) | $5.12 | Feb. 23, 2018 | 31,333 | Disposed |
| Feb. 22, 2017 | AORT | Stock Options (Right to Buy) | Common Stock (16,667) | $7.01 | Feb. 22, 2017 | 16,667 | Disposed |
| Feb. 19, 2016 | AORT | Stock Option (Right to Buy) | Common Stock (418) | $4.83 | Feb. 23, 2016 | 418 | Disposed |
| Feb. 19, 2016 | AORT | Stock Option (Right to Buy) | Common Stock (14,582) | $4.83 | Feb. 23, 2016 | 14,582 | Disposed |
| Feb. 19, 2016 | AORT | Stock Option (Right to Buy) | Common Stock (20,713) | $10.24 | Feb. 19, 2022 | 20,713 | Acquired |
| Feb. 19, 2015 | AORT | Stock Option (Right to Buy) | Common Stock (20,425) | $11.00 | Feb. 19, 2022 | 20,425 | Acquired |
| Feb. 26, 2014 | AORT | Stock Option (Right to Buy) | Common Stock (10,000) | $9.97 | Feb. 26, 2021 | 10,000 | Acquired |
| Nov. 27, 2013 | AORT | Stock Option | Common Stock (25,000) | $9.06 | Aug. 2, 2014 | 25,000 | Disposed |
| Feb. 15, 2013 | AORT | Stock Option (Right to Buy) | Common Stock (10,000) | $6.12 | Feb. 15, 2020 | 10,000 | Acquired |
| Feb. 18, 2012 | AORT | Stock Option | Common Stock (8,332) | $5.67 | Feb. 18, 2019 | 8,332 | Acquired |
| Feb. 23, 2011 | AORT | Stock Option | Common Stock (31,333) | $5.12 | Feb. 23, 2018 | 31,333 | Acquired |
| Feb. 22, 2010 | AORT | Stock Option | Common Stock (16,667) | $7.01 | Feb. 22, 2017 | 16,667 | Acquired |
| Feb. 23, 2009 | AORT | Stock Option | Common Stock (15,000) | $4.83 | Feb. 23, 2016 | 15,000 | Acquired |
| Feb. 28, 2008 | AORT | Stock Option | Common Stock (11,750) | $2.20 | Feb. 29, 2008 | 11,750 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 5 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Oct. 29, 2007 | AORT | Common Stock | — | Direct |
| Oct. 29, 2007 | AORT | Stock Option→ Common Stock (11,750) | 11,750 | Direct |
| Oct. 29, 2007 | AORT | Stock Option→ Common Stock (20,000) | 20,000 | Direct |
| Oct. 29, 2007 | AORT | Stock Option→ Common Stock (1,500) | 1,500 | Direct |
| Oct. 29, 2007 | AORT | Stock Option→ Common Stock (25,000) | 25,000 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
AORT
President, Clinical Research| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2014 | $283,000 | $22,640 | — | — | $61,534 | — | $5,113 | $612,487 |
| 2013 | $270,000 | $21,600 | — | — | $72,845 | — | $5,021 | $515,066 |
| 2012 | $265,000 | $21,200 | — | — | $95,289 | — | $4,858 | $499,507 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.